0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-3 R alpha

IL-3 R alpha

IL-3 R alpha Molecule Information

Name:Interleukin-3 receptor subunit alpha
Target Synonym:Interleukin-3 Receptor Subunit Alpha,Interleukin-3 Receptor alpha Subunit,IL3RY,IL3RX,IL-3R Subunit Alpha,CD123 Antigen,IL-3RA,IL-3 Receptor Alpha SP2 Isoform,Interleukin 3 Receptor Subunit Alpha,IL3RAY,IL3R,IL-3 Receptor Subunit Alpha,HIL-3Ra,Interleukin
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Approved

IL-3 R alpha Protein Product ListCompare or Buy

IL-3 R alpha Part of Bioactivity data

ILA-H5252-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-IL-3 R alpha Antibody, Human IgG1 immobilized on CM5 Chip can bind Human IL-3 R alpha, Fc Tag (Cat. No. ILA-H5252) with an affinity constant of 50.3 nM as determined in a SPR assay (Biacore T200) (QC tested).

ILA-M52H4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Mouse IL-3 R alpha, His Tag (Cat. No. ILA-M52H4) captured on CM5 Chip via anti-His antibody can bind Mouse IL-3, Tag Free with an affinity constant of 0.704 μM as determined in SPR assay (Biacore T200) (QC tested).

IL-3 R alpha Molecule Synonym Name

IL3R,IL3RA,IL-3Ra,IL-3R-alpha,IL3RAY,IL3RX,IL3RY,CD123 antigen,CD123,hIL3Ra,hIL-3Ra,MGC34174,IL-3 R alpha

IL-3 R alpha Molecule Background

Interleukin 3 receptor alpha (low affinity) (IL3RA), also known as CD123 (Cluster of Differentiation 123) is a 70-kD glycoprotein member of the hematopoietin receptor superfamily. This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. The interleukin-3 receptor α chain (CD123) has been identified as a potential immunotherapeutic target because it is overexpressed in AML compared with normal hematopoietic stem cells.

IL-3 R alpha References

IL-3 R alpha Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tagraxofusp-erzs SL-401; DTIL-3; DT388 IL3 Approved Texas A&M University Development Foundation Elzonris EU Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma s:25:"Stemline Therapeutics Inc"; 2018-12-21 Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma Details

IL-3 R alpha Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
KHK-2823 KHK-2823 Phase 1 Clinical Kyowa Hakko Kirin Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Leukemia, Myeloid, Acute Details
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) Phase 1 Clinical Wuhan Union Hospital Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Southwest Hospital) Phase 2 Clinical Southwest Hospital Chongqing Leukemia, Myeloid Details
CD123 CAR-T cells (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia, Myeloid, Acute Details
UniCAR-T-CD-123 UniCAR-T-CD123 Phase 1 Clinical Gemoab Monoclonals Gmbh Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
APVO436 APVO-436 Phase 1 Clinical Aptevo Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute Details
CD123 CAR-T cell therapy Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Leukemia, Myeloid; Leukemia; Leukemia, Myeloid, Acute Details
Flotetuzumab MGD-006; S-80880 Phase 2 Clinical Macrogenics Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Leukemia, Myeloid, Acute Details
Anti-CD123 chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Leukemia, Myeloid, Acute Details
JNJ-63709178 JNJ-9178; CNTO-9958; JNJ-63709178 Phase 1 Clinical Janssen Global Services Llc, Genmab Leukemia, Myeloid, Acute Details
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Leukemia, Myeloid, Acute Details
CSL-360 IL-3Rα; CSL-360 Phase 1 Clinical Csl Ltd Leukemia, Myeloid, Acute Details
Talacotuzumab CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL Phase 3 Clinical Csl Ltd Myelodysplastic Syndromes; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute Details
Vibecotamab XmAb-14045 Phase 1 Clinical Xencor Hematologic Neoplasms; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
IMGN-632 IMGN-632 Phase 2 Clinical Immunogen Myeloproliferative Disorders; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
MB-102 (Mustang Bio) MB-102 Phase 2 Clinical Mustang Bio, City Of Hope National Medical Center Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details
UCART-123 UCART-123 Phase 1 Clinical Cellectis Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop